ScholarIQanswers from OpenAlex

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

PaperCitations, authors & open-access status

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor is a paper indexed in ScholarIQ from OpenAlex.

How many citations does P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor have?

ScholarIQcitation count

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor has 1 citations in the OpenAlex counts ScholarIQ stores.

When was P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor published?

ScholarIQyear

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor has 2018 year in the ScholarIQ index.

What is the open-access status of P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor?

ScholarIQoa status

P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor has bronze oa status in the ScholarIQ index.

What is the DOI of P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor?

ScholarIQdoi

The DOI for P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor is on the source record.

What is the OpenAlex record for P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor?

ScholarIQopenalex

The OpenAlex for P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial